S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
S&P 500   3,865.09 (-1.54%)
DOW   31,632.63 (-1.03%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   231.53 (-1.29%)
FB   257.92 (-2.42%)
GOOGL   2,038.03 (-2.20%)
AMZN   3,102.09 (-1.82%)
TSLA   701.50 (-5.46%)
NVDA   539.13 (-7.04%)
BABA   244.50 (-2.33%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.32 (-6.83%)
AMD   83.56 (-3.89%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.34 (-1.60%)
BA   221.14 (-3.58%)
NFLX   541.93 (-2.07%)
BAC   36.32 (-0.16%)
Log in
OTCMKTS:RGBOQ

ReGen Biologics Stock Forecast, Price & News

$0.04
0.00 (0.00 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.04
Now: $0.04
$0.04
50-Day Range
$0.01
MA: $0.02
$0.05
52-Week Range
$0.00
Now: $0.04
$0.06
VolumeN/A
Average Volume18,471 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReGen Biologics Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics Inc. was formerly known as Aros Corp and changed its name to ReGen Biologics Inc. in November, 2002. ReGen Biologics Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RGBOQ
CUSIPN/A
CIKN/A
Phone201-651-5140
Employees15
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.17 out of 5 stars

Medical Sector

1760th out of 1,957 stocks

Surgical & Medical Instruments Industry

151st out of 168 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$0.04
0.00 (0.00 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGBOQ News and Ratings via Email

Sign-up to receive the latest news and ratings for RGBOQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ReGen Biologics (OTCMKTS:RGBOQ) Frequently Asked Questions

What stocks does MarketBeat like better than ReGen Biologics?

Wall Street analysts have given ReGen Biologics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ReGen Biologics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are ReGen Biologics' key executives?

ReGen Biologics' management team includes the following people:
  • Mr. William G. Rodkey D.V.M., VP of Scientific Affairs (Age 73)

Who are some of ReGen Biologics' key competitors?

What is ReGen Biologics' stock symbol?

ReGen Biologics trades on the OTCMKTS under the ticker symbol "RGBOQ."

How do I buy shares of ReGen Biologics?

Shares of RGBOQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ReGen Biologics' stock price today?

One share of RGBOQ stock can currently be purchased for approximately $0.04.

How many employees does ReGen Biologics have?

ReGen Biologics employs 15 workers across the globe.

What is ReGen Biologics' official website?

The official website for ReGen Biologics is www.regenbio.com.

Where are ReGen Biologics' headquarters?

ReGen Biologics is headquartered at 411 HACKENSACK AVENUE 10TH FLOOR, HACKENSACK NJ, 07601.

How can I contact ReGen Biologics?

ReGen Biologics' mailing address is 411 HACKENSACK AVENUE 10TH FLOOR, HACKENSACK NJ, 07601. The company can be reached via phone at 201-651-5140 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.